Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 352

1.

The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY.

Ferrari R, Fox KM.

Eur Heart J. 2015 Apr 28. pii: ehv150. [Epub ahead of print] Review. No abstract available.

PMID:
25920402
2.

Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.

Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG; CLARIFY Investigators.

PLoS One. 2015 Apr 27;10(4):e0125164. doi: 10.1371/journal.pone.0125164. eCollection 2015.

3.

Heart rate and B-blockade in stable coronary artery disease in Greece.

Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg G, Fox KM, Greenlaw N, Vardas PE.

Hellenic J Cardiol. 2015 Mar-Apr;56(2):112-7.

4.

Hematologic and biochemical reference intervals for adult Friesian horses from North America.

Sample SH, Fox KM, Wunn D, Roth E, Friedrichs KR.

Vet Clin Pathol. 2015 Feb 26. doi: 10.1111/vcp.12248. [Epub ahead of print]

PMID:
25727137
5.
6.

Serial changes in high-sensitivity cardiac troponin, N-terminal pro-B-type natriuretic peptide, and heart fatty acid binding protein during exercise echocardiography in patients with suspected angina pectoris and normal resting left ventricular function.

de Silva R, Tsujioka H, Gaze D, Banya WA, Shah BN, Zoppelaro G, Hersey J, Gonzalez AM, Collins P, Collinson PO, Senior R, Fox KM.

Clin Chem. 2015 Mar;61(3):554-6. doi: 10.1373/clinchem.2014.228536. Epub 2015 Jan 16. No abstract available.

PMID:
25595439
7.

Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort.

Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg PG, Fox KM, Greenlaw N, Ferrari R, Vardas PE.

Hellenic J Cardiol. 2014 Nov-Dec;55(6):442-7.

8.

Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry.

Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM; Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators.

JAMA Intern Med. 2014 Oct;174(10):1651-9. doi: 10.1001/jamainternmed.2014.3773.

PMID:
25110899
9.

Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.

Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari R, Tardif JC, Tendera M, Greenlaw N, Steg PG; CLARIFY Investigators.

PLoS One. 2014 Jul 22;9(7):e102335. doi: 10.1371/journal.pone.0102335. eCollection 2014.

10.

Synthesis, characterization, crystal structures and biological activity of set of Cu(II) benzothiazole complexes: artificial nucleases with cytotoxic activities.

Steiner RA, Foreman D, Lin HX, Carney BK, Fox KM, Cassimeris L, Tanski JM, Tyler LA.

J Inorg Biochem. 2014 Aug;137:1-11. doi: 10.1016/j.jinorgbio.2014.04.002. Epub 2014 Apr 12.

PMID:
24794274
11.

Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke.

Lavallée PC, Labreuche J, Fox KM, Lavados P, Mattle H, Steg PG, Amarenco P; PERFORM, OPTIC, and AMISTAD Investigators.

Neurology. 2014 May 27;82(21):1905-13. doi: 10.1212/WNL.0000000000000456. Epub 2014 Apr 30.

PMID:
24789867
12.

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.

Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P; PERFORM and SPARCL Investigators and Committees.

Stroke. 2014 May;45(5):1429-36. doi: 10.1161/STROKEAHA.113.004229. Epub 2014 Apr 15.

13.

Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.

Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR.

Adv Ther. 2014 Apr;31(4):410-25. doi: 10.1007/s12325-014-0110-3. Epub 2014 Mar 7.

PMID:
24604700
14.
15.

Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.

Cooper C, Fox KM, Borer JS.

Osteoporos Int. 2014 Feb;25(2):737-45. doi: 10.1007/s00198-013-2582-4. Epub 2013 Dec 10.

16.

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.

Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW.

J Med Econ. 2014 Jan;17(1):1-10. doi: 10.3111/13696998.2013.856314. Epub 2013 Oct 31.

PMID:
24131136
17.

Foundational concepts and underlying theories for majors in "biochemistry and molecular biology".

Tansey JT, Baird T Jr, Cox MM, Fox KM, Knight J, Sears D, Bell E.

Biochem Mol Biol Educ. 2013 Sep-Oct;41(5):289-96. doi: 10.1002/bmb.20727. Epub 2013 Sep 10.

PMID:
24019234
18.

Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study.

Khalid JM, Globe G, Fox KM, Chau D, Maguire A, Chiou CF.

BMC Dermatol. 2013 Aug 19;13:9. doi: 10.1186/1471-5945-13-9.

19.

Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.

Blume SW, Fox KM, Joseph G, Chuang CC, Thomas J, Gandra SR.

Adv Ther. 2013 May;30(5):517-27. doi: 10.1007/s12325-013-0034-3. Epub 2013 Jun 6.

20.

Health-related quality of life association with weight change in type 2 diabetes mellitus: perception vs. reality.

Grandy S, Fox KM, Bazata DD; SHIELD Study Group.

Int J Clin Pract. 2013 May;67(5):455-61. doi: 10.1111/ijcp.12093.

PMID:
23574105
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk